Caloglu, M.Yurut-Caloglu, V.Karagol, H.Bayir-Angin, G.Turan, F. N.Uzal, C.2024-06-122024-06-1220091107-06252241-6293https://hdl.handle.net/20.500.14551/19706Purpose: To evaluate the survival of patients with glioblastoma multiforme (GBM) and analyse the prognostic Actors influencing survival. Patients and methods: Seventy-eight consecutive patients with GBM treated with radiotherapy (RT) and temozolomide (TMZ) (in 21 patients) between 1999 and 2006 were retrospectively analysed. Results: Sixty-seven (85.5%) patients had undergone gross total or subtotal resection before RT The median overall survival was 9.8 months, and significantly influenced by age (p=0.02), Karnofsky performance status (p=0.001), RT (p<0.0001), gender (p=0.02), concomitant TMZ (p=0.003), RT waiting time (p=0.014), and treatment time (p=0.01) in univariate analysis. In multivariate analysis, older age (p=0.03), male gender (p=0.01), absence of concomitant TMZ (p=0.008), RT dose below 60 Gy (p=0.03), RT waiting time more than 20 days (p=0.01), and treatment time more than 76 days (p=0.0072) were poor prognosticators. Conclusion: This study emphasizes the importance of female gender, dose and duration of RT and RT waiting time in patients with glioblastoma multiforme.eninfo:eu-repo/semantics/closedAccessChemotherapyGenderGlioblastoma MultiformePrognostic FactorsRadiotherapySurvivalGrowth-Factor ReceptorMultivariate-AnalysisAdjuvant TemozolomideMalignant GliomasSurvival-TimeRadiotherapyResectionIrradiationOncologyTherapyArticle142211218Q4WOS:0002676102000062-s2.0-6765102783019650168Q3